In this podcast recorded live at ESMO 2024 in Barcelona, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Prof. Hiroshi Kitamura (JP) about his presentation on the JCOG1019 study results: An open-label, non-inferiority, randomised phase III study comparing the effectiveness of watchful waiting (WW) and intravesical Bacillus Calmette-Guérin (BCG) in patients with high-grade pT1 (HGT1) bladder cancer with pT0 on the second transurethral resection (TUR) specimen.
Prof. Kitamura shares details of the study rationale, summarises the results, and discusses how these results could be implemented into clinical practice.